Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Carbon quantum dots for cancer theranostics: structure-mechanism relationships and translational perspectives.

Created on 15 Nov 2026

Authors

Shamsheeth Khan Sardar Khan, Selvaraj Brito Raj, Ganesan Padmini Tamilarasi, Govindaraj Sabarees

Published in

Medical oncology (Northwood, London, England). Volume 43. Issue 12. Nov 14, 2026. Epub Nov 14, 2026.

Abstract

Carbon quantum dots (CQDs) have attracted increasing attention as metal-free fluorescent nanomaterials for integrated cancer diagnosis and therapy due to their ultrasmall size, tunable photoluminescence, favorable aqueous dispersibility, and adaptable surface chemistry. However, despite rapid expansion of the field, significant challenges remain regarding emission reproducibility, mechanistic interpretation of red/near-infrared fluorescence, batch-to-batch variability, and clinical translation. This review critically examines recent advances in CQDs synthesis strategies and correlates structural features including defect states, heteroatom doping, and surface functionalization with biological performance in oncology. Particular emphasis is placed on mechanistic classifications of CQDs systems as redox amplifiers, ferroptosis inducers, photodynamic/photothermal agents, nucleus-targeting platforms, and immune-activating nanoconstructs. Rather than cataloguing applications by tumor type, we analyze how specific physicochemical attributes dictate intracellular trafficking, organelle interactions, reactive oxygen species generation, and therapeutic selectivity. We further discuss limitations associated with NIR emission stability, molecular fluorophore artifacts, scalability of synthetic routes, pharmacokinetics, long-term biosafety, and regulatory considerations that currently hinder clinical translation. By integrating structure-property-mechanism relationships with translational readiness assessment, this review provides a critical framework for rational design of next-generation CQDs-based cancer nanotheranostics and identifies key priorities required for future clinical advancement.

PMID:
43033342
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement